Shanghai, June 15, 2026 – Bioengineering’s 2026 new product launch event, themed Swiss Craftsmanship, Shaping Biomanufacturing, took place in Shanghai.
The landmark gathering reflected on over five decades of Bioengineering’s technological expertise since its founding but also unveiled a groundbreaking new product portfolio, accelerating the implementation of innovative therapies and ushering in a new chapter in biomanufacturing.
The event kicked off with a keynote speech address by Mr. Tang Weihua, Senior Vice President of Morimatsu International and CEO of Morimatsu LifeSciences, who officially unveiled the brand-new product portfolio.
“Last year, Bioengineering officially joined Morimatsu Group, marking an important milestone.” Mr. Tang stated. “As a global leader in high-end equipment and engineering solutions, Morimatsu, combined with Bioengineering’s more than 50 years of experience in the R&D of bioreactors and fermentation systems, will bring more comprehensive and innovative solutions to customers worldwide. China is one of the most dynamic markets for innovative biopharmaceuticals globally. The new products launched at this event not only inherit the precision engineering heritage of Switzerland but have also been comprehensively optimized to address the practical needs of biopharmaceutical companies in China. Our high-efficiency, stable technical platforms will shorten R&D timelines and help biotech firms achieve seamless commercialization.”
Witnessed by all the guests and industry partners on-sit at the event, Bioengineering officially debuted five new core products. This product series is designed to address the challenges posed by the rapid development and technological evolution of the biopharmaceutical industry, redefining the role of laboratory equipment.
New Product Portfolio Official Launch
Taberis Xpert Bench-Top Bioreactor
Taberis Prime Bench-Top Bioreactor
Taberis Parasmart Parallel Bioreactor
Ondalis Single-use Wave Bioreactor
Bagento Single-use Bioreactor
Mr. Stefan Anders Bartsch, Product Manager at Bioengineering, delivered a detailed on-site interpretation of the technical strengths and core parameters of the five new products. Together, the five products form a full-process, integrated biomanufacturing platform that covers laboratory R&D, pilot scale-up and large-scale commercial production.
The portfolio advances three core industry transitions: from standalone equipment to integrated platform workflows, from experience-based trial-and-error to data-driven bioprocessing, and from isolated lab workflows to fully interconnected end-to-end manufacturing pipelines.
Bioengineering also showcased the upgraded BIOSCADA II Intelligent Process Control Platform, presented in detail by Product Manager Mr. Ahmad Asraf. This unified solution centralizes bioprocess workflows, streamlines operational complexity and elevates overall production performance. Featuring an intuitive human-machine interface, modular scalable architecture, and robust data analytics & audit trail logging capabilities, BIOSCADA II is the ideal control backbone to enable efficient, fully transparent and expandable biomanufacturing operations. During the equipment demonstration session, guests had hands-on viewing access to the newly launched devices firsthand.
Bio’s technical team conducted product demonstrations and operational briefings, engaging in practical and in-depth discussions with attendees regarding the new products’ technical specifications, application scenarios, and future development trends.
More than fifty years of engineering expertise have laid the groundwork for Bioengineering’s next chapter of growth. Faced with the rapidly evolving biopharmaceutical sector, Bio will continue to uphold the rigor and dedication of “Swiss craftsmanship.” With a more forward-looking R&D and strategic innovation, Bio will drive the global biopharmaceutical industry toward a new era of greater efficiency, intelligence, and sustainability, delivering robust technical support to advance global life sciences industry.
About Bioengineering AG
Bioengineering AG is a leading European company specializing in the development, design, and manufacturing of advanced bioreactor systems. With over 50 years of experience, the company has built a strong worldwide reputation for technical excellence. Its global client base benefits from a comprehensive technology portfolio that spans the entire spectrum of bioreaction, and cultivation needs—from laboratory R&D and pilot-scale studies to industrial-scale production. Bioengineering AG provides end-to-end bioreactor and cultivation systems that deliver reliable support for innovation and commercialization in biotechnology.
Website：www.bioengineering.ch
About Morimatsu LifeSciences
Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Bioengineering AG, Pharmadule Morimatsu AB, and its affiliated companies.
Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.
Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.
Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.
As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.
